Search

Multiple myeloma bone disease is the most common complication of multiple myeloma, which mutually promotes the progression of multiple myeloma, severely affects patients' survival quality and prognosis. Recently, many studies revealed that non-coding RNAs play an important role in the imbalance of bone remodeling by regulating gene expression and participating in various signaling pathways. Additionally, most bone lesions fail to heal even when myeloma patients are in complete remission due to the sustained suppression of osteoblast activity, while non-coding RNAs may become a novel research field and clinical intervention targets. In this review, the latest research advances of non-coding RNAs which affect the occurrence and progress of multiple myeloma bone disease are summarized briefly.非编码RNA在多发性骨髓瘤骨病中调控作用的最新研究进展. 多发性骨髓瘤骨病是多发性骨髓瘤最常见的并发症，与骨髓瘤的进展相互促进，严重影响患者的生存质量和预后。近年来，许多研究揭示了非编码RNA通过调控基因表达和参与多种信号通路，直接或间接在骨重建失衡中发挥重要作用。另外，由于成骨细胞活性被持续抑制，即使骨髓瘤患者处于完全缓解期，大多数骨损伤也无法愈合，而非编码RNA可作为新的研究方向和临床干预靶点。本文对影响多发性骨髓瘤骨病发生和进展的非编码RNA的最新研究进展作一综述.

Some non-coding RNAs (ncRNA), as functional RNA molecules, lack potential to encode proteins, but can affect gene expression and disease progression through a variety of mechanisms. In multiple myeloma (MM), cardiovascular disease is one of the most common complications, which may be related to a variety of factors, including patient's own factors, disease-related factors, drug factors, etc. Non-coding RNA is considered to be an important regulator of cardiovascular event risk factors and cell function, and an important candidate target for improving the condition and prognostic assessment. This article briefly summarized the role of non-coding RNA in cardiac amyloidosis caused by MM, damage to the heart by inflammatory factors, and heart disease caused by chemotherapy drugs in recent years.非编码RNA在多发性骨髓瘤伴有心脏病变中的研究进展.部分非编码RNA作为功能性RNA分子，虽然缺乏编码蛋白质的潜力，但可以通过多种机制影响基因的表达和疾病的进展。在多发性骨髓瘤中，心血管疾病是最常见的合并症之一，其可能与患者自身相关，也与疾病本身、药物治疗等有关。非编码RNA被认为是心血管事件危险因素和细胞功能的重要调节因子，是改善病情和预后评估的重要候选靶标。本文就近年来在多发性骨髓瘤导致的心脏淀粉样变性、炎性因子对心脏的损害和化疗药物导致的心脏病变中，非编码RNA发挥的作用作一综述。.

To study the optimal examination method of CD62P and CD63 and investigate platelet activation in patients with diabetes mellitus (DM), whole blood labeled directly with monoclonal antibodies CD62P and CD63 and flow cytometry were used to evaluate the positive percentages and the mean fluorescence intensity of CD62P and CD63. The specimens of peripheral blood obtained from 10 healthy adults were divided into two groups. In the unfixing group, the positive percentages of CD62P and CD63 at the periods of 30, 60, 90 and 120 minutes after staining were (7.57 +/- 2.33)%, (20.50 +/- 5.70)%, (28.70 +/- 5.67)% and (36.52 +/- 6.13)%, and, (0.89 +/- 0.36)%, (1.11 +/- 0.84)%, (2.35 +/- 2.02)% and (5.43 +/- 3.66)% respectively, their respective MFI were 1.57 +/- 0.13, 1.88 +/- 0.08, 2.00 +/- 0.09 and 2.38 +/- 0.22 and 3.91 +/- 0.11, 4.07 +/- 0.16, 4.38 +/- 0.14 and 4.44 +/- 0.19. However, in fixing group with 1% paraformaldehyde, the results had not any obvious change and almost were same. Besides it, the positive percentages of CD62P and CD63 in 37 adult patients with DM were (14.11 +/- 6.68)% and (2.71 +/- 1.74)%, significantly higher than that in the normal controls. It is concluded that the CD62P and CD63 on platelet membrane were very sensitive and would be easily activated in vitro, all manipulations that includes labeling with antibody, incubation and detection using flow cytometry should be finished within 30 minutes after samples collected. While fixing by using 1% paraformaldehyde can steady the labeling compounds and effectively prevent the artificial activation of platelet, and keep the stable results within two hours after the samples labeled. In adult patients with DM, the relationship between the cardiovascular complication of diabetes and platelet activation might be existed.